Foresite Capital Management V, LLC - Q1 2021 holdings

$340 Million is the total value of Foresite Capital Management V, LLC's 20 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .

 Value Shares↓ Weighting
CGEM NewCullinan Oncology, Inc.$113,818,0002,731,410
+100.0%
33.46%
GMTX NewGemini Therapeutics, Inc.$32,996,0002,435,125
+100.0%
9.70%
ACRS NewAclaris Therapeutics, Inc.$31,708,0001,258,243
+100.0%
9.32%
PHVS NewPharvaris N.V.$18,583,000664,142
+100.0%
5.46%
HIMS NewHims & Hers Health, Inc.$13,983,0001,056,922
+100.0%
4.11%
OLK NewOlink Holding ABsponsored ads$7,200,000200,000
+100.0%
2.12%
FSII NewFS Development Corp. II$6,001,000602,500
+100.0%
1.76%
LHDX NewLucira Health, Inc.$5,869,000485,000
+100.0%
1.72%
RACB NewResearch Alliance Corp. II$5,125,000500,000
+100.0%
1.51%
IMVT NewImmunovant, Inc.$802,00050,000
+100.0%
0.24%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-05-17
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Kinnate Biopharma Inc.12Q3 202325.8%
Hims & Hers Health, Inc.11Q3 202337.5%
Aclaris Therapeutics, Inc.11Q3 202315.4%
Pharvaris N.V.11Q3 20235.5%
Quantum-Si Incorporated9Q2 202311.3%
TheseusPharmaceuticals, Inc.8Q3 202324.4%
Somalogic, Inc.8Q2 202320.5%
Compass Therapeutics, Inc.8Q3 202317.2%
Pardes Biosciences Inc7Q2 202337.8%
Gemini Therapeutics, Inc.7Q3 20229.7%

View Foresite Capital Management V, LLC's complete holdings history.

Latest filings
TypeFiled
42024-04-05
13F-HR2024-02-13
13F-HR2023-11-13
42023-08-31
13F-HR2023-08-11
42023-07-19
13F-HR2023-05-12
42023-05-10
42023-04-06
42023-02-22

View Foresite Capital Management V, LLC's complete filings history.

Compare quarters

Export Foresite Capital Management V, LLC's holdings